New drugs could reach market sooner as govt halves trial review timeline

The Indian government is shaking up the pharmaceutical sector by slashing the review period for manufacturing applications for new drugs to 45 days. Now, manufacturers can initiate clinical trials or bioequivalence studies with just a prior notification to the regulators, ditching the old requirement for express permission.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Np3P9nl
via IFTTT

Read More

Bastar's first super-specialty hospital opens

Bastar region will soon have its first super specialty hospital. Located in Jagdalpur, the facility opens in February. Hyderabad-based Continental Hospitals partners with the Chhattisgarh government. This 240-bedded hospital will offer advanced medical services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4FoeWz6
via IFTTT

Read More

Budget 2026: Industry leaders seek funding framework for innovation, R&D in pharma, MedTech

Industry leaders are calling for a structured funding framework in the upcoming Union Budget. This aims to boost innovation and R&D in India's pharmaceutical and MedTech sectors. The goal is to drive advanced research and achieve the Viksit Bharat vision. Companies seek support for complex therapies and improved patient access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GsVdtYK
via IFTTT

Read More

Zydus launches biosimilar for treatment of multiple cancers

Zydus Lifesciences has launched Tishtha, the world's first biosimilar of Nivolumab, in India. This drug treats multiple cancers. Tishtha will be available in 100 mg and 40 mg dosages. The prices are significantly lower than the reference drug. This launch expands access to immuno-oncology therapies. The company aims to support patients with consistent care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mgIh9iF
via IFTTT

Read More

Over 160 drug samples found sub-standard in December

A recent inspection by India's drug regulator has revealed a troubling statistic: 167 medication samples were classified as not of standard quality (NSQ) in December, with valuable insights from both central and state laboratories aiding the findings. Many of these samples consisted of widely used drugs, highlighting a critical need for heightened quality control.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5euzjas
via IFTTT

Read More

CDSCO finds over 160 drug samples as 'not of standard quality' for December

In December 2025, 74 drug samples were identified as Not of Standard Quality (NSQ) by Central Drugs Laboratories and 93 by State Drugs Testing Laboratories. Additionally, seven spurious drug samples were identified across various zones, manufactured by unauthorized entities. These findings are part of routine regulatory surveillance to ensure market safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pmvjSGU
via IFTTT

Read More

Drug maker Lupin inks licensing pact with Galenicum for injectable Semaglutide

Drug maker Lupin announced a significant partnership. Its subsidiary, Lupin Atlantis Holdings SA, has signed an agreement with Galenicum Health. This collaboration focuses on diabetes and weight management medication, specifically injectable Semaglutide. Galenicum will handle development and manufacturing. Lupin will manage regulatory submissions, approvals, and commercialisation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z3k2BLK
via IFTTT

Read More